AANEM News Express

AANEM News Express

Science News: Anti-MAG Antibodies in 202 Patients: Clinicopathological and Therapeutic Features

1/15/2018
 
Submitted by Francisco E. Gomez, MD, News Science Editorial Board
Edited by Lisa M. Williams, MD, News Science Editorial Board
 
Svahn, J, Petiot P, Antoine JC et al. Anti-MAG antibodies in 202 patients: clinicopathological and therapeutic features. Journal of Neurology, Neurosurgery & Psychiatry. Oct 2017; pii: jnnp-2017-316715. doi: 10.1136/jnnp-2017-316715
 
In this study, the authors characterize neuropathy arising from anti-myelin-associated-glycoprotein (anti-MAG) antibodies, as an IgM monoclonal gammopathy in order to assess the pathologic features and clinical management of anti-MAG associated neuropathies. They evaluated 202 patients, 65.8% male, with a mean age of 62.6 years, with emphasis on the typical and atypical phenotypes. Typical neuropathy phenotypes included patients with sensory ataxia and distal polyneuropathy with or without neuropathic tremor and progressive motor deficits in lower limbs. Atypical neuropathy phenotypes included patients with GBS-like manifestations, chronic sensorimotor polyradiculoneuropathies, small fiber neuropathies, or asymmetric/multifocal neuropathy.
 
Rituximab was the most commonly employed treatment in Anti-MAG neuropathy in this study and it was administered to 45.5% of the study population. Although about 33% of the treated patients responded favorably, another 12% exhibited reversible and fleeting clinical worsening during or after Rituximab. The authors did note an association between earlier treatment during the disease course and stabilization or improvement.
 
Comments: This study is the largest Anti-MAG cohort evaluated to date, painting a clearer picture of the disease manifestations and management including use of rituximab. MGUS is not an uncommon entity and this study highlights the need to keep anti-MAG workup in mind in certain patients with neuropathies which may portend better outcomes by expediting appropriate treatment. 


View Related News Stories:

  EducationScience News


Recent AANEM News

Science News: Lacosamide in Patients With Nav1.7 Mutations-related Small Fibre Neuropathy: A Randomized Controlled Trial

Science News: Indications for Neuromuscular Ultrasound: Expert Opinion and Review of the Literature

Science News: A Novel Treatment Strategy for Severe Guillain-Barre Syndrome: The Zipper Method

Science News: Six-Month Assessment of a Hand Prosthesis with Intraneural Tactile Feedback

Dr. Peter Grant’s Expert Testimony Helps Convict Texas Doctor and Hospital Owner in $20 Million Healthcare Fraud Scheme





Advertisement

TPP

Advertisement

ABEM

Advertisement

Find Your Dream Job